Cargando…
Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
Glioblastoma (GBM) is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable. A variety of treatment options are currently being explored to improve patient survival, including small molecule inhibitors, viral therapies, cancer vaccines, and monoclonal antib...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279645/ https://www.ncbi.nlm.nih.gov/pubmed/35847506 http://dx.doi.org/10.1016/j.apsb.2021.12.019 |
_version_ | 1784746444993855488 |
---|---|
author | Liu, Hui Qiu, Weimin Sun, Tianyu Wang, Lei Du, Chenxi Hu, Yanyu Liu, Wenyuan Feng, Feng Chen, Yao Sun, Haopeng |
author_facet | Liu, Hui Qiu, Weimin Sun, Tianyu Wang, Lei Du, Chenxi Hu, Yanyu Liu, Wenyuan Feng, Feng Chen, Yao Sun, Haopeng |
author_sort | Liu, Hui |
collection | PubMed |
description | Glioblastoma (GBM) is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable. A variety of treatment options are currently being explored to improve patient survival, including small molecule inhibitors, viral therapies, cancer vaccines, and monoclonal antibodies. Among them, the unique advantages of small molecule inhibitors have made them a focus of attention in the drug discovery of glioblastoma. Currently, the most used chemotherapeutic agents are small molecule inhibitors that target key dysregulated signaling pathways in glioblastoma, including receptor tyrosine kinase, PI3K/AKT/mTOR pathway, DNA damage response, TP53 and cell cycle inhibitors. This review analyzes the therapeutic benefit and clinical development of novel small molecule inhibitors discovered as promising anti-glioblastoma agents by the related targets of these major pathways. Meanwhile, the recent advances in temozolomide resistance and drug combination are also reviewed. In the last part, due to the constant clinical failure of targeted therapies, this paper reviewed the research progress of other therapeutic methods for glioblastoma, to provide patients and readers with a more comprehensive understanding of the treatment landscape of glioblastoma. |
format | Online Article Text |
id | pubmed-9279645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-92796452022-07-15 Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds Liu, Hui Qiu, Weimin Sun, Tianyu Wang, Lei Du, Chenxi Hu, Yanyu Liu, Wenyuan Feng, Feng Chen, Yao Sun, Haopeng Acta Pharm Sin B Review Glioblastoma (GBM) is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable. A variety of treatment options are currently being explored to improve patient survival, including small molecule inhibitors, viral therapies, cancer vaccines, and monoclonal antibodies. Among them, the unique advantages of small molecule inhibitors have made them a focus of attention in the drug discovery of glioblastoma. Currently, the most used chemotherapeutic agents are small molecule inhibitors that target key dysregulated signaling pathways in glioblastoma, including receptor tyrosine kinase, PI3K/AKT/mTOR pathway, DNA damage response, TP53 and cell cycle inhibitors. This review analyzes the therapeutic benefit and clinical development of novel small molecule inhibitors discovered as promising anti-glioblastoma agents by the related targets of these major pathways. Meanwhile, the recent advances in temozolomide resistance and drug combination are also reviewed. In the last part, due to the constant clinical failure of targeted therapies, this paper reviewed the research progress of other therapeutic methods for glioblastoma, to provide patients and readers with a more comprehensive understanding of the treatment landscape of glioblastoma. Elsevier 2022-04 2021-12-31 /pmc/articles/PMC9279645/ /pubmed/35847506 http://dx.doi.org/10.1016/j.apsb.2021.12.019 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Liu, Hui Qiu, Weimin Sun, Tianyu Wang, Lei Du, Chenxi Hu, Yanyu Liu, Wenyuan Feng, Feng Chen, Yao Sun, Haopeng Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds |
title | Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds |
title_full | Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds |
title_fullStr | Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds |
title_full_unstemmed | Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds |
title_short | Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds |
title_sort | therapeutic strategies of glioblastoma (gbm): the current advances in the molecular targets and bioactive small molecule compounds |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279645/ https://www.ncbi.nlm.nih.gov/pubmed/35847506 http://dx.doi.org/10.1016/j.apsb.2021.12.019 |
work_keys_str_mv | AT liuhui therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT qiuweimin therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT suntianyu therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT wanglei therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT duchenxi therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT huyanyu therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT liuwenyuan therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT fengfeng therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT chenyao therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds AT sunhaopeng therapeuticstrategiesofglioblastomagbmthecurrentadvancesinthemoleculartargetsandbioactivesmallmoleculecompounds |